Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study
There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results. A total of 318 subjects with HIV RNA levels of >1000 copies/mL were enrolled in 41 centers throughout Italy from 2001 through 2003, stratified on the basis of t...
Saved in:
| Published in: | Clinical infectious diseases Vol. 42; no. 10; p. 1470 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
15.05.2006
|
| Subjects: | |
| ISSN: | 1537-6591, 1537-6591 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results.
A total of 318 subjects with HIV RNA levels of >1000 copies/mL were enrolled in 41 centers throughout Italy from 2001 through 2003, stratified on the basis of their drug history, randomized (1:1) to 2 arms to have their treatments modified on the basis of the results of HIV genotyping (as interpreted by virtual phenotype analysis or with use of a rule-based interpretation system), and followed up for 48 weeks. At least 1 nucleoside reverse-transcriptase inhibitor and 1 protease inhibitor had to be included in any new regimen; nonnucleoside reverse-transcriptase inhibitor-naive patients were also prescribed a nonnucleoside reverse-transcriptase inhibitor. Only drugs licensed in Italy were allowed. The primary end point was a decrease in HIV RNA level to <400 copies/mL by week 12 according to on-treatment analysis.
The mean (+/- standard deviation) values at baseline were as follows: HIV RNA level, 4.1+/-0.74 log(10) copies/mL; CD4(+) T lymphocyte count, 410+/-262 cells/microL; reverse-transcriptase mutations, 4.8+/-2.9; and protease mutations, 2.8+/-2.5. There were 133 patients (41.8%) who were nonnucleoside reverse-transcriptase inhibitor naive and protease inhibitor experienced, 63 patients (19.8%) who were nonnucleoside reverse-transcriptase inhibitor experienced and protease inhibitor naive, and 122 patients (38.4%) who were 3-class experienced. A total of 192 patients completed 12 weeks of the treatment regimen assigned at baseline; at 12 weeks, 66.3% of patients in the virtual phenotype arm and 71.3% of patients in the rule-based interpretation arm had HIV RNA levels of <400 copies/mL (P = .46). No statistically significant difference between arms was observed by intention-to-treat analysis.
Both the virtual phenotype and rule-based interpretation methods of HIV genotyping can guide the selection of effective antiretroviral drugs for a salvage regimen. |
|---|---|
| AbstractList | There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results.
A total of 318 subjects with HIV RNA levels of >1000 copies/mL were enrolled in 41 centers throughout Italy from 2001 through 2003, stratified on the basis of their drug history, randomized (1:1) to 2 arms to have their treatments modified on the basis of the results of HIV genotyping (as interpreted by virtual phenotype analysis or with use of a rule-based interpretation system), and followed up for 48 weeks. At least 1 nucleoside reverse-transcriptase inhibitor and 1 protease inhibitor had to be included in any new regimen; nonnucleoside reverse-transcriptase inhibitor-naive patients were also prescribed a nonnucleoside reverse-transcriptase inhibitor. Only drugs licensed in Italy were allowed. The primary end point was a decrease in HIV RNA level to <400 copies/mL by week 12 according to on-treatment analysis.
The mean (+/- standard deviation) values at baseline were as follows: HIV RNA level, 4.1+/-0.74 log(10) copies/mL; CD4(+) T lymphocyte count, 410+/-262 cells/microL; reverse-transcriptase mutations, 4.8+/-2.9; and protease mutations, 2.8+/-2.5. There were 133 patients (41.8%) who were nonnucleoside reverse-transcriptase inhibitor naive and protease inhibitor experienced, 63 patients (19.8%) who were nonnucleoside reverse-transcriptase inhibitor experienced and protease inhibitor naive, and 122 patients (38.4%) who were 3-class experienced. A total of 192 patients completed 12 weeks of the treatment regimen assigned at baseline; at 12 weeks, 66.3% of patients in the virtual phenotype arm and 71.3% of patients in the rule-based interpretation arm had HIV RNA levels of <400 copies/mL (P = .46). No statistically significant difference between arms was observed by intention-to-treat analysis.
Both the virtual phenotype and rule-based interpretation methods of HIV genotyping can guide the selection of effective antiretroviral drugs for a salvage regimen. There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results.BACKGROUNDThere is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results.A total of 318 subjects with HIV RNA levels of >1000 copies/mL were enrolled in 41 centers throughout Italy from 2001 through 2003, stratified on the basis of their drug history, randomized (1:1) to 2 arms to have their treatments modified on the basis of the results of HIV genotyping (as interpreted by virtual phenotype analysis or with use of a rule-based interpretation system), and followed up for 48 weeks. At least 1 nucleoside reverse-transcriptase inhibitor and 1 protease inhibitor had to be included in any new regimen; nonnucleoside reverse-transcriptase inhibitor-naive patients were also prescribed a nonnucleoside reverse-transcriptase inhibitor. Only drugs licensed in Italy were allowed. The primary end point was a decrease in HIV RNA level to <400 copies/mL by week 12 according to on-treatment analysis.METHODSA total of 318 subjects with HIV RNA levels of >1000 copies/mL were enrolled in 41 centers throughout Italy from 2001 through 2003, stratified on the basis of their drug history, randomized (1:1) to 2 arms to have their treatments modified on the basis of the results of HIV genotyping (as interpreted by virtual phenotype analysis or with use of a rule-based interpretation system), and followed up for 48 weeks. At least 1 nucleoside reverse-transcriptase inhibitor and 1 protease inhibitor had to be included in any new regimen; nonnucleoside reverse-transcriptase inhibitor-naive patients were also prescribed a nonnucleoside reverse-transcriptase inhibitor. Only drugs licensed in Italy were allowed. The primary end point was a decrease in HIV RNA level to <400 copies/mL by week 12 according to on-treatment analysis.The mean (+/- standard deviation) values at baseline were as follows: HIV RNA level, 4.1+/-0.74 log(10) copies/mL; CD4(+) T lymphocyte count, 410+/-262 cells/microL; reverse-transcriptase mutations, 4.8+/-2.9; and protease mutations, 2.8+/-2.5. There were 133 patients (41.8%) who were nonnucleoside reverse-transcriptase inhibitor naive and protease inhibitor experienced, 63 patients (19.8%) who were nonnucleoside reverse-transcriptase inhibitor experienced and protease inhibitor naive, and 122 patients (38.4%) who were 3-class experienced. A total of 192 patients completed 12 weeks of the treatment regimen assigned at baseline; at 12 weeks, 66.3% of patients in the virtual phenotype arm and 71.3% of patients in the rule-based interpretation arm had HIV RNA levels of <400 copies/mL (P = .46). No statistically significant difference between arms was observed by intention-to-treat analysis.RESULTSThe mean (+/- standard deviation) values at baseline were as follows: HIV RNA level, 4.1+/-0.74 log(10) copies/mL; CD4(+) T lymphocyte count, 410+/-262 cells/microL; reverse-transcriptase mutations, 4.8+/-2.9; and protease mutations, 2.8+/-2.5. There were 133 patients (41.8%) who were nonnucleoside reverse-transcriptase inhibitor naive and protease inhibitor experienced, 63 patients (19.8%) who were nonnucleoside reverse-transcriptase inhibitor experienced and protease inhibitor naive, and 122 patients (38.4%) who were 3-class experienced. A total of 192 patients completed 12 weeks of the treatment regimen assigned at baseline; at 12 weeks, 66.3% of patients in the virtual phenotype arm and 71.3% of patients in the rule-based interpretation arm had HIV RNA levels of <400 copies/mL (P = .46). No statistically significant difference between arms was observed by intention-to-treat analysis.Both the virtual phenotype and rule-based interpretation methods of HIV genotyping can guide the selection of effective antiretroviral drugs for a salvage regimen.CONCLUSIONBoth the virtual phenotype and rule-based interpretation methods of HIV genotyping can guide the selection of effective antiretroviral drugs for a salvage regimen. |
| Author | Lazzarin, Adriano Torti, Carlo Castelli, Paula Kenna, Paula Mc Di Carlo, Aldo Gianotti, Nicola Tarquini, Pierluigi Guaraldi, Giovanni Rossi, Maria Cristina Mezzaroma, Ivano Ladisa, Nicoletta Chiesa, Elisabetta Mondino, Vincenzo Boeri, Enzo Keulen, Wilco |
| Author_xml | – sequence: 1 givenname: Nicola surname: Gianotti fullname: Gianotti, Nicola email: nicola.gianotti@hsr.it organization: Clinica di Malattie Infettive, Università Vita-Salute San Raffaele, Milan, Italy. nicola.gianotti@hsr.it – sequence: 2 givenname: Vincenzo surname: Mondino fullname: Mondino, Vincenzo – sequence: 3 givenname: Maria Cristina surname: Rossi fullname: Rossi, Maria Cristina – sequence: 4 givenname: Elisabetta surname: Chiesa fullname: Chiesa, Elisabetta – sequence: 5 givenname: Ivano surname: Mezzaroma fullname: Mezzaroma, Ivano – sequence: 6 givenname: Nicoletta surname: Ladisa fullname: Ladisa, Nicoletta – sequence: 7 givenname: Giovanni surname: Guaraldi fullname: Guaraldi, Giovanni – sequence: 8 givenname: Carlo surname: Torti fullname: Torti, Carlo – sequence: 9 givenname: Pierluigi surname: Tarquini fullname: Tarquini, Pierluigi – sequence: 10 givenname: Paula surname: Castelli fullname: Castelli, Paula – sequence: 11 givenname: Aldo surname: Di Carlo fullname: Di Carlo, Aldo – sequence: 12 givenname: Enzo surname: Boeri fullname: Boeri, Enzo – sequence: 13 givenname: Wilco surname: Keulen fullname: Keulen, Wilco – sequence: 14 givenname: Paula Mc surname: Kenna fullname: Kenna, Paula Mc – sequence: 15 givenname: Adriano surname: Lazzarin fullname: Lazzarin, Adriano |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16619162$$D View this record in MEDLINE/PubMed |
| BookMark | eNplkc1OAyEURompUVv1EQwrd6MwdJipO9P408TEjbptmOEyxTAwAqOpj-uTiLYaEzeXm3yH85EwRiPrLCB0TMkZJRU_LwgreLWDDmjByowXMzr6s--jcQjPhFBakWIP7VPO6Yzy_AB9zF3XC6-Ds9gpLLAfDGS1CCCxMK3zOq46_JZmyvoVWBfX_X9AOY_jCrC2EXzvIYqoN8bbxRNut9dCynE7aKlti4Mwr6IF7KHVHdjvLMGZtgqamOx9coCNAdfrr3cJK12n31PQGG11IwyOXgtz8V3cDZvKgBP36w5xkOtDtKuECXC0PSfo8frqYX6b3d3fLOaXd1kzrfKY5aVipOCy5KJmRCgqOYCasVrOSM5lAdNKFZVkrKGUAaFcTWmpcgrTnCjKST5Bpxtv793LACEuOx0aMEZYcENY8rLinBGWwJMtONQdyGXvdSf8evnzK_kn9KyT-g |
| CitedBy_id | crossref_primary_10_1097_01_COH_0000247388_00862_bb crossref_primary_10_1002_jmv_21152 crossref_primary_10_1002_jmv_21261 |
| ContentType | Journal Article |
| CorporateAuthor | Mutations and Salvage (MuSa) Study Group |
| CorporateAuthor_xml | – name: Mutations and Salvage (MuSa) Study Group |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1086/503568 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-6591 |
| ExternalDocumentID | 16619162 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GroupedDBID | --- ..I .2P .GJ .I3 .ZR 08P 0R~ 1TH 29B 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAYOK ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABLJU ABNGD ABNHQ ABOCM ABPLY ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ACGFO ACGFS ACHIC ACPRK ACUFI ACUTO ACYHN ADBBV ADGZP ADHKW ADHZD ADIPN ADJQC ADQBN ADRIX ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AFXEN AGINJ AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AI. AIAGR AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN AQKUS AQVQM ASPBG ATGXG AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C1A C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DCCCD DIK DILTD DOOOF DU5 D~K E3Z EBS ECM EE~ EIF EJD EMOBN ENERS ESX F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H5~ HAR HQ3 HTVGU HVGLF HW0 HZ~ IOX IPSME J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JSODD JST KAQDR KBUDW KOP KSI KSN L7B M49 MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NPM NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 VH1 W8F X7H YAYTL YKOAZ YXANX ZGI ~91 ~S- 7X8 ABPQP ACUKT ADNBA ADQXQ AEMQT AGQPQ AJBYB AJNCP ALXQX JXSIZ |
| ID | FETCH-LOGICAL-c482t-27f3056d76ab30af1d6eef93bd9026d5e48f58d33c113e016f417f21e420f1602 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 12 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000237247400020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1537-6591 |
| IngestDate | Wed Oct 01 10:06:51 EDT 2025 Wed Feb 19 01:46:22 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c482t-27f3056d76ab30af1d6eef93bd9026d5e48f58d33c113e016f417f21e420f1602 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://academic.oup.com/cid/article-pdf/42/10/1470/783533/42-10-1470.pdf |
| PMID | 16619162 |
| PQID | 67866303 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_67866303 pubmed_primary_16619162 |
| PublicationCentury | 2000 |
| PublicationDate | 2006-05-15 |
| PublicationDateYYYYMMDD | 2006-05-15 |
| PublicationDate_xml | – month: 05 year: 2006 text: 2006-05-15 day: 15 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical infectious diseases |
| PublicationTitleAlternate | Clin Infect Dis |
| PublicationYear | 2006 |
| SSID | ssj0011805 |
| Score | 1.8833423 |
| Snippet | There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results.
A total of 318... There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results.BACKGROUNDThere is... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1470 |
| SubjectTerms | Adult Algorithms Anti-HIV Agents - therapeutic use Antiretroviral Therapy, Highly Active Female Genotype HIV - genetics HIV Infections - drug therapy HIV Protease Inhibitors - therapeutic use Humans Italy Male Middle Aged Mutation Phenotype Reverse Transcriptase Inhibitors - therapeutic use RNA, Viral - blood RNA, Viral - genetics Salvage Therapy Viral Load |
| Title | Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/16619162 https://www.proquest.com/docview/67866303 |
| Volume | 42 |
| WOSCitedRecordID | wos000237247400020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwELZ4CfVCy6vQ0uIDV4s4tuMEVaoqBKIHVhwA7W3l-LGstJssZBeJ_tz-Emby4CGEeugll7HHkTye-TwzniHkwGljQ-4cM8omTEqvWR7ngmVR5J1OJAi2q5tN6F4v7feziwXyo3sLg2mVnU6sFbUrLfrID0GpgnGMxM_pLcOeURhbbRtoLJJlAUAGE7p0_zmGwNM6gRGOtGaJyviLzkIqEipJ3weVtXE5_fh_v_WJrLWgkv5qpGCdLPhig6yet2HzTfL3-KnbIC0DNfRuPvYMDZijZjwEjrObCUWXLNAw6atEz-ybAYBvKeBFOnqVqIgcz35f02E7rQI6Hc5HaBRpZcb3oLEo9n-YwI0ZaTCYNTlgwL2t61rR_AH_yxSunIz-AKF7sknrviJH9cKTebNkRWHcE--6Qu4WuTo9uTw-Y21zB2ZlGs9YrAPeXkAeTC4iE7hLvA-ZyF0G10KnvEyDSp0QlnPhAZgGyXWIuZdxFHgSxdtkqSgLv0NoLlKprLEuMRLrrWXScmuyEOIsci7Xu2S_27sBHB6MiJjCl_Nq0O3eLvncbP9g2tT4GHDALYCc4y__nPuVfGjcMopxtUeWA6gN_42s2PvZqLr7XsskfHsX549KWvLV |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+a+rule-based+algorithm+with+a+phenotype-based+algorithm+for+the+interpretation+of+HIV+genotypes+in+guiding+salvage+regimens+in+HIV-infected+patients+by+a+randomized+clinical+trial%3A+the+mutations+and+salvage+study&rft.jtitle=Clinical+infectious+diseases&rft.au=Gianotti%2C+Nicola&rft.au=Mondino%2C+Vincenzo&rft.au=Rossi%2C+Maria+Cristina&rft.au=Chiesa%2C+Elisabetta&rft.date=2006-05-15&rft.eissn=1537-6591&rft.volume=42&rft.issue=10&rft.spage=1470&rft_id=info:doi/10.1086%2F503568&rft_id=info%3Apmid%2F16619162&rft_id=info%3Apmid%2F16619162&rft.externalDocID=16619162 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon |